Peregrine Pharmaceuticals (PPHM) Earnings: An Early Look – Celgene Corporation (CELG)
Earnings season is winding down, with most companies already having reported their quarterly results.
Posts Tagged ‘NASDAQ:CELG’
3 Humongous Health-Care Stocks This Week: Celgene Corporation (CELG), Celldex Therapeutics, Inc. (CLDX)
The Dow set an all-time high, but it still was up only 2% for the week. If you want returns to really get excited about, look no further than the health-care sector.
Analyst Roundtable: Any Surprises in Amarin Corporation plc (ADR) (AMRN)’s Fourth Quarter?
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
2 Sides of Celgene Corporation (CELG)’s Apremilast Results
Celgene Corporation (NASDAQ:CELG) has good news -- and it has bad news.
Why Investors Should Love Celgene Corporation (CELG)’s Apremilast
Celgene Corporation (NASDAQ:CELG) shareholders didn't have to wait long for good news in 2013. On Jan.
More Upside on this Biotechnology Giant: Celgene Corporation (CELG)
The Food and Drug Administration added Celgene Corporation (NASDAQ:CELG)’s Pomalyst to the list of approved drugs last Friday.
Pomalyst Takes the Stage: Celgene Corporation (CELG), Johnson & Johnson (JNJ), Onyx Pharmaceuticals, Inc. (ONXX)
Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year.
Celgene Corporation (CELG)’s New Acquisition — of Celgene
Celgene Corporation (NASDAQ:CELG) announced on Wednesday a $600 million deal to buy a stake in a growing biotech with several successful products on the market and a strong pipeline...
Celgene Corporation (CELG)’s Fastest-Growing Drug
What's the fastest growing drug in Celgene Corporation (NASDAQ:CELG)'s portfolio? It isn't Revlimid, Vidaza, or Abraxane.
Celgene Corporation (CELG): My Favorite Big Biotech for 2013
The biggest biopharmaceutical companies blazed trails and lifted portfolios last year.
Amgen, Inc. (AMGN)’s Future Is Brighter Than You Might Think
When you think about a cutting-edge, one-foot-in-the-future biotech company, no one would blame you for skipping over Amgen, Inc. (NASDAQ:AMGN).
Peregrine Pharmaceuticals (PPHM)’s Epic Failure (Maybe)
Clinical trial 101 says if a trial passes all of its primary endpoints it's successful. If it doesn't, it's not.
Develop Your Own Successful Dividend Portfolio: The Procter & Gamble Company (PG), Oceaneering International (OII)
I am well into my 12th year of investing and have a passion for investing in dividend paying companies.
Celgene Corporation (CELG)’s Fading Star
Celgene Corporation (NASDAQ:CELG) has plenty of stars in its product portfolio. Revlimid currently stands as the brightest of the bunch.
Can Johnson & Johnson (JNJ) Hold Its Ground in the Multiple Myeloma Market?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
What’s Next for Sarepta Therapeutics Inc (SRPT)?
What's next for Sarepta Therapeutics Inc (NASDAQ:SRPT) ? After announcing encouraging results last October from a phase 2b study of eteplirsen targeting treatment of Duchenne...
More Good News for Celgene Corporation (CELG)
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene Corporation (NASDAQ:CELG)'s Pomalyst in treating patients with multiple myeloma.
This Week in Biotech: Celgene Corporation (CELG) Biogen Idec Inc. (BIIB)
With the SPDR S&P Biotech Index up 21% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Has GlaxoSmithKline plc (GSK) Become the Perfect Stock?
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Celgene Corporation (CELG): Still Revving Up With Revlimid
What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months.
Buy, Sell, or Hold: Astex Pharmaceuticals, Inc. (ASTX)
When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons and decide whether its possible upside outweighs its risks.
3 Biotechs Burning Through Cash: Keryx Biopharmaceuticals (KERX), Peregrine Pharmaceuticals (PPHM) and More
Young, upstart pharmaceutical and biotech companies do one thing that almost no other industry does. They go years without generating any revenue.
